Immunotoxicology of Biopharmaceutics☆
Helen G. Haggerty(Bristol-Myers Squibb (Germany)), Jacintha Shenton(Janssen (Belgium)), Karen Price(Purchase College)
Cited by 0
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection
|American Journal of Transplantation|2017|96